Compositions comprising pneumococcal antigens
AssigneeNovartis AG
InventorsClaudio DONATI, Alessandro MUZZI, Vega MASIGNANI, Fabio BAGNOLI, Paolo RUGGIERO, Michèle Anne BAROCCHI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens.
Claims17
(canceled)
An immunogenic composition comprising a combination of S. pneumoniae antigens, said combination comprising a spr0096 antigen and a spr2021 antigen.
A polypeptide of formula NH2—A{—X—L—}n—B—COOH, wherein:
- X is an amino acid sequence of a pneumococcal antigen, selected from the group consisting of:
- (1) a spr0057 antigen;
- (2) a spr0096 antigen;
- (3) a spr0565 antigen;
- (4) a spr2021 antigen;
- (5) a RrgA antigen;
- and (6) a RrgB antigen;
- L is an optional linker amino acid sequence;
- A is an optional N-terminal amino acid sequence;
- B is an optional C-terminal amino acid sequence, and
- n is an integer of 2 or more and at least one instance of X is spr0096 and at least one instance of X is spr2021.
A polypeptide having 75% or more sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 194 and 205.
A pneumococcus in which the spr2021 and spr0096 polypeptides have been knocked out, optionally wherein one or more of the following peptides has/have also been knocked out:
- (1) spr0057;
- (2) spr0286;
- (3) spr0565;
- (4) spr1098;
- (5) spr1345;
- (6) spr1416;
- (7) spr1418;
- (8) spr0867;
- (9) spr1431;
- (10) spr1739;
- (11) spr1433;
- and/or (12) spr1707.
Dependencies are inferred from the claim text.